The Scottish Medicines Consortium (SMC) recently accepted three new medicines for the treatment of four medical conditions within NHS Scotland.
The medicines are:
- Pembrolizumab (keytruda)
- Bevacizumab (avastin)
- Edoxaban (lixiana)
Pembrolizumab (keytruda) was accepted for routine use in patients with skin cancer (melanoma) previously untreated with ipilimumab. But due to uncertainty around the extent of clinical effectiveness, pembrolizumab could not be approved for skin cancer patients who had previously been treated with ipilimumab.
Bevacizumab (avastin) was approved following a resubmission for its use as an initial treatment in combination with chemotherapy for patient with advanced ovarian cancer. And edoxaban (Lixiana), an oral anticoagulant gained acceptance for treatment of deep vein thrombosis and pulmonary embolism and for the prevention of stroke in patients with atrial fibrillation.
To read more, click here: SMC November 2015 Medicine decisions